


IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1 (currently amended). A compound ~~of general formula I~~, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I:



Formula I

[[where]] wherein:

~~R₁ is selected from the group formed by H, -(CH₂)₃-, -(CH₂)₄-, CH₂-S-CH₂-, S-CH₂-CH₂-;~~

R₂ is selected from the group ~~formed by~~ consisting of N, NH and S; wherein
if R₂ is N, then R₁ is selected from the group consisting of -(CH₂)₃-,
(CH₂)₄-, -CH₂SCH₂, and -SCH₂CH₂-;

if R₂ is S or NH, then R₁ is absent;

if R₂ is NH, then n is 1;

n has a value of [[0]] zero or 1;



Z is selected from the group ~~formed by~~ consisting of ~~C₂-C₁₀-alkyl~~ C₂-C₁₀-alkyl,
~~C₂-C₁₀-alkenyl~~ C₂-C₁₀-alkenyl, and ~~C₂-C₁₀-alkynyl~~ C₂-C₁₀-alkynyl;


R₃ is selected from the group ~~formed by~~ consisting of H, ~~C₁-C₁₀-alkyl~~ C₁-C₁₀-alkyl,
aryl, and aralkyl;

m has a value of [[0]] zero, [[to]] 1, or 2;

R₄ is selected from the group ~~formed by~~ consisting of O[[,]] and CH₂;

R_5 is selected from the group ~~formed by:~~ consisting of





[[where]] wherein:

R₆ is selected from the group ~~formed by~~ consisting of H, ~~C1-C5-alkyl~~ C₁-C₅-alkyl, ~~C1-C5-alkoxy~~ C₁-C₅-alkoxy, OH, F, Cl, Br, and I;

X is selected from the group ~~formed by~~ consisting of O, S, NH, and NCH₃;

Y is selected from the group ~~formed by~~ consisting of O[[,]] and NH;



W is selected from the group ~~formed by~~ consisting of S[[,]] and NH[[;]]

~~and their salts and solvates.~~

2 (currently amended). [[A]] The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1, characterized in that wherein:

Z ~~represents is a C2-C10-alkyl~~ C₂-C₁₀-alkyl; [[group]] and

R₅ is selected from the group ~~formed by~~ consisting of



[[where]] wherein:


R₆ is selected from the group ~~formed by~~ consisting of H, ~~C1-C5-alkyl~~ C₁-C₅-alkyl, ~~C1-C5-alkoxyl~~ C₁-C₅-alkoxyl, OH, F, Cl, Br, and I.

3 (currently amended). [[A]] The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1, characterized in that wherein:

Z is butyl[[,]];

R₃ is H; and


R₅ is selected from the group ~~formed by~~ consisting of



[[where]] wherein:

R₆ is selected from the group ~~formed by~~ consisting of H, ~~C1-C5-alkyl~~ C₁-C₅-alkyl, ~~C1-C5-alkoxyl~~ C₁-C₅-alkoxyl, OH, F, Cl, Br, and I.

4 (currently amended). A process to prepare a compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer, according to claim 1 characterized in that: wherein the compound corresponds in structure to Formula I:



Formula I

wherein:

R₂ is selected from the group consisting of N, NH and S; wherein

if R₂ is N, then R₁ is selected from the group consisting of -(CH₂)₃-, (CH₂)₄-, -CH₂SCH₂-, and -SCH₂CH₂-;

if R₂ is S or NH, then R₁ is absent;

if R₂ is NH, then n is 1;

n has a value of zero or 1;


Z is selected from the group consisting of C₂-C₁₀-alkyl, C₂-C₁₀-alkenyl, and C₂-C₁₀-alkynyl;

R₃ is selected from the group consisting of H, C₁-C₁₀-alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R₄ is selected from the group consisting of O and CH₂;

R₅ is selected from the group consisting of



wherein:

R_6 is selected from the group consisting of H, C₁-C₅-alkyl, C₁-C₅-alkoxyl, OH, F, Cl, Br, and I;


X is selected from the group consisting of O, S, NH, and NCH₃;

Y is selected from the group consisting of O and NH; and

W is selected from the group consisting of S and NH


comprising:

[[A)] reacting the intermediate halogen derivatives II are made to react compounds according to Formula II, where L means Cl, Br, with compounds according to Formula amines III in acetonitrile, according to [[the]] scheme of reaction I:



or

[[B)] reacting the compounds of Formula the intermediate amines IV are made to react with the compounds of Formula suitable halogen derivatives V, where L means Cl, Br, in acetonitrile, according to [[the]] scheme of reaction II:



[[where]] wherein:


L is selected from the group consisting of Cl and Br; and

the definitions of R₁, R₂, n, Z, m, R₄ and R₅ ~~in these schemes~~ are identical to those ~~previously made for the products of the invention in Formula I.~~

5 (currently amended). A process according to claim 4, ~~characterized in that those~~ wherein compounds with R₃ ~~different from H~~ selected from the group consisting of C₁-C₁₀-alkyl, aryl and aralkyl are obtained by alkylation of the analogues wherein R₃ is hydrogen.

6 (currently amended). A pharmaceutical composition ~~characterized in that it~~ comprises comprising a therapeutically effective quantity of ~~any of the compounds a~~ compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically

acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I defined in claim 1,



wherein:

R₂ is selected from the group consisting of N, NH and S; wherein

if R₂ is N, then R₁ is selected from the group consisting of -(CH₂)₃-, (CH₂)₄-, -CH₂SCH₂, and -SCH₂CH₂-;

if R₂ is S or NH, then R₁ is absent;

if R₂ is NH, then n is 1;

n has a value of zero or 1;


Z is selected from the group consisting of C₂-C₁₀-alkyl, C₂-C₁₀-alkenyl, and C₂-C₁₀-alkynyl;


R₃ is selected from the group consisting of H, C₁-C₁₀-alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R₄ is selected from the group consisting of O and CH₂;

R₅ is selected from the group consisting of





wherein:

R_6 is selected from the group consisting of H, C_1 - C_5 -alkyl, C_1 - C_5 -alkoxyl, OH, F, Cl, Br, and I;

X is selected from the group consisting of O, S, NH, and NCH_3 ;

Y is selected from the group consisting of O and NH;

W is selected from the group consisting of S and NH;

~~together with a~~ and one or more pharmaceutically acceptable carriers or excipients.

7 (currently amended). ~~The use of a compound according to claim 1, for the production of a medicine~~ The method according to claim 19 for the treatment and/or prevention of a pathological ~~states~~ state wherein ~~[[the]]~~ a 5-HT_{1A} receptor ~~agonists are~~ agonist is indicated.

8 (currently amended). ~~The use of a compound according to claim 1, for the production of a medicine~~ The method according to claim 21 wherein the neuroprotection provided comprises ~~[[for]]~~ the treatment and/or prophylaxis of cerebral damage produced by thromboembolic stroke or cranium-brain traumatic injuries.

9. (new). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1 selected from the group consisting of

(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-b]thiazol;
(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-c]-thiazol;
(±)-3-[4-[(Chroman-2-yl)methylamine]butyl]-2,4-dioxothiazolidin;
(±)-3-[5-[(Chroman-2-yl)methylamine]pentyl]-2,4-dioxothiazolidin;
(±)-3-[6-[(Chroman-2-yl)methylamine]hexyl]-2,4-dioxothiazolidin;
2-[4-[(Naphth-1-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[(Naphth-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[2-(Naphth-1-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
3-[4-[2-(Naphth-1-yl)ethylamine]butyl]-2,4-dioxothiazolidin;
2-[4-[2-(Naphth-2-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[2-(Phenoxy)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
3-[4-[2-(Phenoxy)ethylamine]butyl]-2,4-dioxothiazolidin;
2-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
3-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-2,4-dioxothiazolidin;
2-[4-[(Benzimidazol-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[(o-Methoxyphenyl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[2-(o-Methoxyphenyl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]-imidazol;
2-[4-[3-(o-Methoxyphenyl)propylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[4-(o-Methoxyphenyl)butylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol; and
2-[3-[3-(o-Methoxyphenyl)propylamine]propyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol.

10 (new). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1 selected from the group consisting of


2-[4-[(chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
3-[4-[(chroman-2-yl)methylamino]butyl]-2,4-dioxothiazolidine;

3-[5-[(chroman-2-yl)methylamino]pentyl]-2,4-dioxothiazolidine;
3-[6-[(chroman-2-yl)methylamino]hexyl]-2,4-dioxothiazolidine;
2-[4-[2-(phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole; and
3-[4-[2-(phenoxy)ethylamino]butyl]-2,4-dioxothiazolidine.

11 (new). The process of claim 4, wherein:

Z is C₂-C₁₀-alkyl; and

R₅ is selected from the group consisting of



wherein:


R₆ is selected from the group consisting of H, C₁-C₅-alkyl, C₁-C₅-alkoxyl, OH, F, Cl, Br, and I.

12 (new). The process of claim 4, wherein:

Z is butyl;

R₃ is H; and

R₅ is selected from the group consisting of



wherein:

R₆ is selected from the group consisting of H, C₁-C₅-alkyl, C₁-C₅-alkoxyl, OH, F, Cl, Br, and I.

13 (new). The process of claim 4, wherein the compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to Formula I is selected from the group consisting of:

(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-b]thiazol;
(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-c]-thiazol;
(±)-3-[4-[(Chroman-2-yl)methylamine]butyl]-2,4-dioxothiazolidin;
(±)-3-[5-[(Chroman-2-yl)methylamine]pentyl]-2,4-dioxothiazolidin;
(±)-3-[6-[(Chroman-2-yl)methylamine]hexyl]-2,4-dioxothiazolidin;
2-[4-[(Naphth-1-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[(Naphth-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[2-(Naphth-1-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
3-[4-[2-(Naphth-1-yl)ethylamine]butyl]-2,4-dioxothiazolidin;
2-[4-[2-(Naphth-2-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[2-(Phenoxy)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
3-[4-[2-(Phenoxy)ethylamine]butyl]-2,4-dioxothiazolidin;
2-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
3-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-2,4-dioxothiazolidin;
2-[4-[(Benzimidazol-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[(o-Methoxyphenyl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[2-(o-Methoxyphenyl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]-imidazol;
2-[4-[3-(o-Methoxyphenyl)propylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[4-(o-Methoxyphenyl)butylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol; and
2-[3-[3-(o-Methoxyphenyl)propylamine]propyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol.

14 (new). The process of claim 4, wherein the compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to Formula I is selected from the group consisting of

2-[4-[(chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;

3-[4-[(chroman-2-yl)methylamino]butyl]-2,4-dioxothiazolidine;

3-[5-[(chroman-2-yl)methylamino]pentyl]-2,4-dioxothiazolidine;

3-[6-[(chroman-2-yl)methylamino]hexyl]-2,4-dioxothiazolidine;


2-[4-[2-(phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole; and

3-[4-[2-(phenoxy)ethylamino]butyl]-2,4-dioxothiazolidine.

15 (new). The pharmaceutical composition of claim 6, wherein:

Z is C₂-C₁₀-alkyl; and

R₅ is selected from the group consisting of



wherein:


R₆ is selected from the group consisting of H, C₁-C₅-alkyl, C₁-C₅-alkoxyl, OH, F, Cl, Br, and I.

16 (new). The pharmaceutical composition of claim 6, wherein:

Z is butyl;

R₃ is H; and

R₅ is selected from the group consisting of



wherein:

R₆ is selected from the group consisting of H, C₁-C₅-alkyl, C₁-C₅-alkoxyl, OH, F, Cl, Br, and I.


17 (new). The pharmaceutical composition of claim 6, wherein the compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to Formula I is selected from the group consisting of

- (±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
- (±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-b]thiazol;
- (±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-c]-thiazol;
- (±)-3-[4-[(Chroman-2-yl)methylamine]butyl]-2,4-dioxothiazolidin;
- (±)-3-[5-[(Chroman-2-yl)methylamine]pentyl]-2,4-dioxothiazolidin;
- (±)-3-[6-[(Chroman-2-yl)methylamine]hexyl]-2,4-dioxothiazolidin;
- 2-[4-[(Naphth-1-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
- 2-[4-[(Naphth-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
- 2-[4-[2-(Naphth-1-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
- 3-[4-[2-(Naphth-1-yl)ethylamine]butyl]-2,4-dioxothiazolidin;
- 2-[4-[2-(Naphth-2-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
- 2-[4-[2-(Phenoxy)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
- 3-[4-[2-(Phenoxy)ethylamine]butyl]-2,4-dioxothiazolidin;
- 2-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
- 3-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-2,4-dioxothiazolidin;
- 2-[4-[(Benzimidazol-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
- 2-[4-[(o-Methoxyphenyl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
- 2-[4-[2-(o-Methoxyphenyl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]-imidazol;
- 2-[4-[3-(o-Methoxyphenyl)propylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
- 2-[4-[4-(o-Methoxyphenyl)butylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol; and

2-[3-[3-(o-Methoxyphenyl)propylamine]propyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol.

18 (new). The pharmaceutical composition of claim 6, wherein the compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to Formula I is selected from the group consisting of 2-[4-[(chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole; 3-[4-[(chroman-2-yl)methylamino]butyl]-2,4-dioxothiazolidine; 3-[5-[(chroman-2-yl)methylamino]pentyl]-2,4-dioxothiazolidine; 3-[6-[(chroman-2-yl)methylamino]hexyl]-2,4-dioxothiazolidine; 2-[4-[2-(phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole; and 3-[4-[2-(phenoxy)ethylamino]butyl]-2,4-dioxothiazolidine.

19 (new). A method for the treatment and/or prevention of a pathological state in a subject in need of such treatment and/or prevention, wherein the method comprises administering to the subject a compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I:



Formula I

wherein:

R_2 is selected from the group consisting of N, NH and S; wherein

if R_2 is N, then R_1 is selected from the group consisting of $-(CH_2)_3-$, $-(CH_2)_4-$, $-CH_2SCH_2-$, and $-SCH_2CH_2-$;

if R_2 is S or NH, then R_1 is absent;

if R_2 is NH, then n is 1;

n has a value of zero or 1;


Z is selected from the group consisting of C₂-C₁₀-alkyl, C₂-C₁₀-alkenyl, and C₂-C₁₀-alkynyl;


R₃ is selected from the group consisting of H, C₁-C₁₀-alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R₄ is selected from the group consisting of O and CH₂;

R₅ is selected from the group consisting of





wherein:

R_6 is selected from the group consisting of H, C_1 - C_5 -alkyl, C_1 - C_5 -alkoxyl, OH, F, Cl, Br, and I;


X is selected from the group consisting of O, S, NH, and NCH_3 ;

Y is selected from the group consisting of O and NH;

W is selected from the group consisting of S and NH.

20 (new). The method according to claim 7, wherein the pathological state is selected from the group consisting of anxiety disorders, depression and mixed disorders of anxiety and depression.

21 (new). A method to provide neuroprotection to a subject in need thereof comprising administering to the subject a neuroprotective amount of a compound, a stereochemical isomer of the compound, or solvate or pharmaceutically acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I:



Formula I

wherein:

R_2 is selected from the group consisting of N, NH and S; wherein

if R_2 is N, then R_1 is selected from the group consisting of $-(CH_2)_3-$, $-(CH_2)_4-$, $-CH_2SCH_2-$, and $-SCH_2CH_2-$;

if R_2 is S or NH, then R_1 is absent;

if R_2 is NH, then n is 1;

n has a value of zero or 1;


Z is selected from the group consisting of C_2 - C_{10} -alkyl, C_2 - C_{10} -alkenyl, and C_2 - C_{10} -alkynyl;


R_3 is selected from the group consisting of H, C_1 - C_{10} -alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R_4 is selected from the group consisting of O and CH_2 ;

R_5 is selected from the group consisting of





wherein:


R_6 is selected from the group consisting of H, C_1 - C_5 -alkyl, C_1 - C_5 -alkoxyl, OH, F, Cl, Br, and I;

X is selected from the group consisting of O, S, NH, and NCH_3 ;

Y is selected from the group consisting of O and NH;

W is selected from the group consisting of S and NH.


22 (new). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1 wherein the compound corresponds in structure to Formula Ib:



Formula Ib

wherein the definition of n, Z, R_3 , m, R_4 and R_5 are identical to those in claim 1.


23 (new). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1 wherein the compound corresponds in structure to Formula Ic:



Formula Ic

wherein the definition of Z, R₃, m, R₄ and R₅ are identical to those in claim 1.


24 (new). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1 wherein the compound corresponds in structure to Formula Id:



Formula Id

wherein the definition of R₁, n, Z, R₃, m, R₄ and R₅ are identical to those in claim 1.

25 (new). A compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I:



Formula I

wherein:

R_2 is selected from the group consisting of N and S; wherein

if R_2 is N, then R_1 is selected from the group consisting of $-(CH_2)_3-$, $-(CH_2)_4-$, $-CH_2SCH_2-$, and $-SCH_2CH_2-$;

if R_2 is S, then R_1 is absent;

n has a value of zero or 1;


Z is selected from the group consisting of C_2 - C_{10} -alkyl, C_2 - C_{10} -alkenyl, and C_2 - C_{10} -alkynyl;


R_3 is selected from the group consisting of H, C_1 - C_{10} -alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R_4 is selected from the group consisting of O and CH_2 ;

R_5 is selected from the group consisting of





wherein:

R_6 is selected from the group consisting of H, C_1 - C_5 -alkyl, C_1 - C_5 -alkoxyl, OH, F, Cl, Br, and I;

X is selected from the group consisting of O, S, NH, and NCH_3 ;

Y is selected from the group consisting of O and NH;

W is selected from the group consisting of S and NH.